NeuroMetrix (NASDAQ:NURO) (NASDAQ: NURO) is a medical technology company specializing in the development and commercialization of diagnostic and therapeutic solutions for neurological conditions. Founded in 1996 and headquartered in Waltham, Massachusetts, the company focuses on point-of-care diagnostics and wearable neuromodulation devices aimed at improving patient outcomes and advancing clinical care. NeuroMetrix markets its products directly to healthcare providers as well as through strategic partnerships and distributors worldwide.
In the diagnostic arena, NeuroMetrix offers DPNCheck, a handheld device designed to facilitate the early detection of diabetic peripheral neuropathy (DPN) in primary care and endocrinology settings. The device measures nerve conduction velocity and sensory nerve action potential in the sural nerve, providing rapid, quantitative data in under three minutes. As a result, clinicians can identify patients at risk for neuropathy sooner and tailor treatment plans accordingly, potentially reducing the incidence of diabetic foot complications.
On the therapeutic side, NeuroMetrix’s flagship consumer product, Quell, is an over-the-counter wearable neurostimulation device indicated for the relief of chronic pain. Worn on the calf, Quell employs high-frequency nerve stimulation to activate the body’s natural pain-relieving mechanisms, enabling users to manage pain without medication. The device has received FDA clearance and is supported by clinical studies demonstrating reductions in pain intensity and improvements in sleep quality for individuals with chronic pain syndromes. NeuroMetrix also markets Sensus, a prescription TENS (transcutaneous electrical nerve stimulation) device tailored for specific pain management applications.
NeuroMetrix distributes its products across North America, Europe, Asia, and select markets in Latin America and the Middle East. Under the leadership of President and CEO Frank M. Cammilleri, the company continues to invest in research and development to expand its product pipeline and enhance the precision of neuromodulation therapies. With an emphasis on innovation and patient-centered design, NeuroMetrix aims to broaden access to diagnostic tools and non-pharmacological pain management solutions globally.
